Cetuximab Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-10
Target enrollment:
Participant gender:
Summary
This study is a single-arm, multi-center, prospective clinical study aimed at exploring the efficacy and safety of cetuximab combined with PRaG regimen in rescuing patients with EGFR-positive advanced refractory solid tumors.